Partner Content Partner Content In-vitro Diagnostics Market profiled Qiagen, Becton Dickinso... In-vitro Diagnostics Market will reach $95bn by 2025
News BioMarin ends year with $4.8bn play for Amicus BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
